Project Grant R01DE033712
Award Date
9/2/24
Completion Date
5/31/29
Dollars Obligated
$1.6M
Federal Agency
National Institute of Dental and Craniofacial Research
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23219, USA
Similar Awards
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $317,000 project grant (CFDA No. 93.121 - Oral Diseases and Disorders Research) to Temple University to investigate the role of amplified protein kinases in head and neck squamous cell carcinoma (HNSCC) progression and therapy resistance. The 2-year project aims to test whether the protein kinase TNIK, which is amplified in 20% of HNSCC cases, sustains HNSCC cell proliferation and viability by activating focal...
This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR, CFDA 93.121 Oral Diseases and Disorders Research) provides $1,403,398 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on head and neck squamous cell carcinoma (HNSCC). The project aims to utilize advanced imaging approaches to develop imaging-based biomarkers related to a hybrid epithelial/mesenchymal state within HNSCC tumors and its...
This $390,000 Project Grant award under the National Institute of Dental and Craniofacial Research's (NIDCR) Oral Diseases and Disorders Research program (CFDA 93.121) supports research at the Medical College of Wisconsin, Inc. to leverage single-cell co-culture and gene expression profiling techniques for identifying tumor antigen-specific T cells in oral squamous cell carcinoma (OSCC). The key objectives are to: 1) Use a high-throughput single-cell co-culture system to isolate and identify...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), is focused on investigating the divergent responses to radio-immunotherapy in head and neck squamous cell carcinoma (HNSCC) and pancreatic adenocarcinoma (PDAC). The $229,440 award aims to elucidate the mechanistic role of regulatory T cells in driving these differential responses, with the goal of improving the efficacy of...
This federal Project Grant award, valued at $164,322.00, was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The award supports research to investigate the evolution of pro-tumoral myeloid cells during the transition from oral epithelial dysplasia to head and neck squamous cell carcinoma, with a focus on the role of the SOX2 oncogene and its impact on the STING immune signaling pathway. The...
This $429,000 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to engineer extracellular vesicles (EEVs) carrying anti-DSG2 single-chain variable fragment (scFv) fusion proteins and miR-155 for therapeutic treatment of head and neck squamous cell carcinoma (HNSCC). The award to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, will support...
This $642,488 Project Grant was awarded on June 10, 2025 by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant supports research to investigate the role of the MARCHF8-autophagy pathway in promoting immune evasion and tumor progression in human papillomavirus (HPV)-positive head and neck squamous cell carcinomas (HPV+ HNSCC). Specifically, the researchers aim to: 1) determine if targeting MARCHF8...
This Project Grant award in the amount of $1,295,508, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports research to develop chemical inhibitors of the NRF2 transcription factor as synthetic combination agents with radiation therapy (RT) to improve treatment for head and neck squamous cell carcinoma (HNSCC). The primary awardee, Washington University, is investigating two distinct NRF2 inhibitors, VVD065 and WCDD115, to determine if they can sensitize...
This $612,048 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) supports research to investigate the role of the lysyl oxidase propeptide (LOX-PP) in regulating macrophage phenotypes and their impact on oral squamous cell carcinoma (OSCC) tumor suppression. The research aims to characterize the differential effects of wildtype versus variant LOX-PP on macrophage activation,...